Deciphera Pharmaceuticals, Inc. Stock price

Equities

DCPH

US24344T1016

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-03-01 pm EST 5-day change 1st Jan Change
17.36 USD +4.01% Intraday chart for Deciphera Pharmaceuticals, Inc. +8.09% +7.63%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Enjoy this offer
* See conditions on site
Sales 2024 * 199M Sales 2025 * 261M Capitalization 1.4B
Net income 2024 * -198M Net income 2025 * -166M EV / Sales 2024 * 5.39 x
Net cash position 2024 * 331M Net cash position 2025 * 200M EV / Sales 2025 * 4.62 x
P/E ratio 2024 *
-7.81 x
P/E ratio 2025 *
-9.84 x
Employees 355
Yield 2024 *
-
Yield 2025 *
-
Free-Float 71.03%
More Fundamentals * Assessed data
Dynamic Chart
Deciphera Pharmaceuticals' Q4 Net Loss Narrows, Revenue Rises MT
Transcript : Deciphera Pharmaceuticals, Inc., Q4 2023 Earnings Call, Feb 06, 2024
Earnings Flash (DCPH) DECIPHERA PHARMACEUTICALS Posts Q4 Revenue $48.3M, vs. Street Est of $46.8M MT
Deciphera Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Deciphera Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
North American Morning Briefing : Rate Doubts Keep -2- DJ
Deciphera Says Long-Term Data Show 'Similar' Overall Survival Rates for Qinlock, Sunitinib MT
Deciphera Pharmaceuticals Partners With Genesis Pharma to Distribute Cancer Drug in 14 European Countries MT
GENESIS Pharma and Deciphera Pharmaceuticals, Inc. Announce an Exclusive Distribution Agreement for RIPRETINIB in 14 European Markets in Central and Eastern Europe CI
Transcript : Deciphera Pharmaceuticals, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 04:30 PM
Deciphera Pharmaceuticals, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Deciphera Pharmaceuticals Announces Nature Medicine Publication of Results from Exploratory ctDNA Analysis from INTRIGUE Phase 3 Study Demonstrating Substantial Clinical Benefit of QINLOCK® in 2L GIST Patients with Mutations in KIT Exon 11 and 17/18 CI
North American Morning Briefing : Fed Decision, -2- DJ
Deciphera Pharmaceuticals Insider Sold Shares Worth $259,256, According to a Recent SEC Filing MT
HC Wainwright Adjusts Deciphera Pharmaceuticals' Price Target to $30 From $25, Keeps Buy Rating MT
More news

Latest transcript on Deciphera Pharmaceuticals, Inc.

1 day+4.01%
1 week+8.09%
Current month+4.01%
1 month+19.89%
3 months+34.16%
6 months+19.39%
Current year+7.63%
More quotes
1 week
16.01
Extreme 16.01
17.73
1 month
13.86
Extreme 13.86
17.73
Current year
13.25
Extreme 13.25
17.73
1 year
9.90
Extreme 9.9
17.73
3 years
6.51
Extreme 6.51
48.27
5 years
6.51
Extreme 6.51
71.11
10 years
6.51
Extreme 6.51
71.11
More quotes
Managers TitleAgeSince
Chief Executive Officer 53 18-05-16
Director of Finance/CFO 53 15-01-31
Chief Tech/Sci/R&D Officer - 22-12-31
Members of the board TitleAgeSince
Director/Board Member 62 16-08-31
Director/Board Member 78 19-06-30
Chairman 57 19-12-03
More insiders
Date Price Change Volume
24-03-01 17.36 +4.01% 950,660
24-02-29 16.69 -0.71% 484,419
24-02-28 16.81 -0.59% 534,331
24-02-27 16.91 +2.86% 597,644
24-02-26 16.44 +2.37% 428,423

Delayed Quote Nasdaq, March 01, 2024 at 04:00 pm EST

More quotes
Deciphera Pharmaceuticals, Inc. is a biopharmaceutical company that is focused on discovering, developing, and commercializing medicines to patients for the treatment of cancer. The Company has developed a switch-control kinase inhibitor platform in kinase biology to execute its strategy to develop a portfolio of medicines. The Company's QINLOCK, is a switch-control kinase inhibitor, engineered using its drug discovery platform and developed for the treatment of fourth-line gastrointestinal stromal tumor (GIST). The Company has two additional clinical-stage assets, vimseltinib and DCC-3116. Vimseltinib is an investigational, orally administered, potent, and highly selective switch-control kinase inhibitor of the colony stimulating factor 1 receptor (CSF1R). Vimseltinib is in a pivotal phase III study in patients with tenosynovial giant cell tumor (TGCT). DCC-3116 is an investigational, orally administered, potent, and highly selective switch-control inhibitor of the ULK kinase.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
17.36 USD
Average target price
23.5 USD
Spread / Average Target
+35.37%
Consensus
  1. Stock
  2. Equities
  3. Stock Deciphera Pharmaceuticals, Inc. - Nasdaq
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.
SIGN UP NOW